Nycomed's Daxas improves lung function in COPD
03 September 2009
Katie McQue
Please Login to read the full article.
03 September 2009
Katie McQue
katie.mcque@informa.com
Nycomed's once-daily oral phosphodiesterase-4 inhibitor Daxas (roflumilast) has demonstrated an improvement in lung function and disease exacerbations in patients with chronic obstructive pulmonary disease (COPD).
The results of its four-trial pivotal Phase III programme were published in...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Nycomed & Merck fail to convince NICE about Daxas in COPD
- Novartis plans US launch of indacaterol inhaler following US thumbs up
- US FDA delays decision on Novartis COPD drug, giving Forest drug a leap ahead
- US COPD approval for Roflumilast despite 2010 complete response letter
ANALYSIS
Other Informa Analysis
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
